insights_auto
Why is CLLS up 2.14%?
Dive Deeperchevron_right
CLLS:NASDAQ
Cellectis SA
$1.43
arrow_upward
+2.14%(+0.030) 1D
$1.43
0.00% (0.00)
bedtimeAfter hours
Closed: Oct 2, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for CLLS...
Open
$1.45
High
$1.47
Low
$1.42
Mkt. cap
106.78M
Avg. vol.
144.02K
Volume
47.51K
52-wk high
$5.48
52-wk low
$1.25
EPS
-$0.65
Beta
3.00
Shares outstanding
72.09M
No. of employees
227
Open
$1.45
High
$1.47
Low
$1.42
Mkt. cap
106.78M
Avg. vol.
144.02K
Volume
47.51K
52-wk high
$5.48
52-wk low
$1.25
EPS
-$0.65
Beta
3.00
Shares outstanding
72.09M
No. of employees
227
News stories
From web sources and news partners
Traders Union
·
55 minutes ago
S&P500 has posted gains in nearly every November-through-June period since 1942, Lia Holmgren notes
InteractiveCrypto
·
6 hours ago
The S&P 500 Looks Strong. Underneath, October Looks Thin.
Forbes
·
8 hours ago
S&P 500 Q3 Earnings Preview: Trends Investors Need To Watch
TradingKey
·
17 hours ago
S&P 500 vs. Nasdaq 100: Which Is Better for Long-Term Investment?
Profile
Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina. Wikipedia
About Cellectis SA